Oregon and Colorado created state-regulated psilocybin programs that operate outside the federal drug approval system. In effect, they are large natural experiments. In August 2026, researchers published the first real-world safety and outcome data from Oregon.

The programs

Oregon. Voters approved psilocybin services in 2020, and licensed access for adults aged 21 and over began in 2023. Clients visit licensed service centers and take psilocybin under the supervision of a licensed facilitator. More than 20,000 people have used Oregon’s services.

Colorado. Colorado has allowed regulated psilocybin since 2024, and unlike Oregon, adults there also have the option of using outside a supervised setting. New Mexico has a similar law taking effect later in 2026.

These are not medical treatments. Facilitators are not necessarily clinicians, and the programs are open to people who want psilocybin for curiosity, self-improvement, or spiritual reasons as well as mental health.

The Oregon study

A multisite cohort study led by Oregon Health & Science University (OHSU), published in JAMA Network Open in 2026, followed 346 adults receiving state-regulated psilocybin services at 24 of Oregon’s 26 licensed centers. Participants were supervised by 83 licensed facilitators and completed assessments before their session and at one week, one month, and three months afterward. About 44% had never used a psychedelic before.

Findings, as reported:

• Serious adverse reactions were uncommon.
• Participants reported high satisfaction.
• On average, mental health, well-being, and life satisfaction improved over the three months, including symptoms of anxiety, depression, and PTSD in people who reported them.

The lead researcher, Todd Korthuis, said he was initially skeptical about giving psilocybin outside a tightly controlled medical setting. Other scientists were surprised that the results looked so promising. One described it as good news that the program didn’t “blow up.”

Why the results should be read carefully

No control group. The study followed people over time but did not compare them with similar people who didn’t receive psilocybin. Improvement could reflect expectation, natural recovery, or the motivation of people who choose to participate.

Self-selected, paying clients. People who seek out and pay for these services differ from patients in clinical trials. Results may not apply to others.

Short follow-up. Three months is helpful but not long-term.

Loss to follow-up. Participants who had a bad experience may be less likely to stay in a study.

Who was left out. The 346 participants are a small slice of the more than 20,000 who have used the program.

Adverse effects. Psychiatrist Albert Garcia-Romeu of Johns Hopkins said he has spoken with numerous people from Oregon who struggled after their psilocybin experience and contacted the Johns Hopkins psychedelic center. This is anecdotal, but it is a reminder that harms can fall outside what a cohort study captures.

What it means

The study adds to the idea that structured, supervised psilocybin sessions can be delivered outside hospitals with a low rate of serious events. It does not show that the sessions caused the improvements, that they are equivalent to clinical treatment, or that they are suitable for people with serious psychiatric conditions. Trials like COMP005 and COMP006 (Article 12) remain the stronger evidence for depression.

Questions for policymakers

• How should facilitators be trained and supervised?
• How should the programs screen for risk, such as psychosis or bipolar disorder?
• What follow-up and support should be required after sessions?
• Who handles complaints and adverse events?
• Should regulated services be open to people seeking treatment for illness, or only for wellness?

Questions for individuals considering a program

• What screening do you do, and how are medications handled?
• What are the facilitators’ qualifications?
• What happens if I have a difficult experience, and what aftercare is available?
• Is this a licensed program in a jurisdiction where it is legal? (In Canada, it isn’t; see Article 19.)

The takeaway

Oregon’s data is reassuring on short-term safety within a regulated setting, but it can’t tell us how well psilocybin works or who might be harmed. It is an important data point, not a verdict.

Sources: HealthDay and NPR coverage of the OHSU study (Aug 2026); JAMA Network Open 2026;9(8):e2630608 as summarized by HMP Global Learning Network.